Fate Therapeutics Future Growth
Future criteria checks 0/6
Fate Therapeutics's earnings are forecast to decline at 9.2% per annum while its annual revenue is expected to grow at 8.6% per year. EPS is expected to grow by 2.1% per annum. Return on equity is forecast to be -55.6% in 3 years.
Key information
-9.2%
Earnings growth rate
2.1%
EPS growth rate
| Biotechs earnings growth | 27.8% |
| Revenue growth rate | 8.6% |
| Future return on equity | -55.6% |
| Analyst coverage | Good |
| Last updated | 09 Dec 2024 |
Recent future growth updates
Recent updates
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
Nov 20Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts
Aug 21
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Aug 11Fate Therapeutics: Looking For A Potential Turnaround In 2024
Apr 29Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 23Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%
Feb 16Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks
Jan 26Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry
Dec 19Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?
Sep 08Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price
Jun 07Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%
May 08Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Apr 17We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
Jan 10Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Sep 22Fate Therapeutics: Yes For Speculators, No For Defensive Investors
Aug 30Needham initiates Fate coverage Therapeutics on potential of stem cell therapies
Jul 28Fate Therapeutics names Brian Powl as chief commercial officer
Jun 30Fate: Possible Speedy FDA Approval Process With RMAT Designation
Jun 03We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
Jun 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4 | -229 | -163 | -119 | 6 |
| 12/31/2025 | 4 | -221 | -167 | -170 | 15 |
| 12/31/2024 | 14 | -186 | -128 | -129 | 14 |
| 9/30/2024 | 13 | -178 | -133 | -132 | N/A |
| 6/30/2024 | 12 | -176 | -141 | -141 | N/A |
| 3/31/2024 | 6 | -190 | -140 | -137 | N/A |
| 12/31/2023 | 64 | -161 | -138 | -132 | N/A |
| 9/30/2023 | 106 | -173 | -184 | -171 | N/A |
| 6/30/2023 | 119 | -212 | -209 | -188 | N/A |
| 3/31/2023 | 137 | -235 | -241 | -212 | N/A |
| 12/31/2022 | 96 | -282 | -284 | -248 | N/A |
| 9/30/2022 | 69 | -294 | -290 | -243 | N/A |
| 6/30/2022 | 68 | -254 | -275 | -221 | N/A |
| 3/31/2022 | 63 | -233 | -257 | -200 | N/A |
| 12/31/2021 | 56 | -212 | -214 | -163 | N/A |
| 9/30/2021 | 55 | -197 | -148 | -113 | N/A |
| 6/30/2021 | 48 | -212 | -131 | -111 | N/A |
| 3/31/2021 | 40 | -185 | -47 | -40 | N/A |
| 12/31/2020 | 31 | -173 | -44 | -39 | N/A |
| 9/30/2020 | 18 | -149 | -49 | -44 | N/A |
| 6/30/2020 | 13 | -117 | -39 | -33 | N/A |
| 3/31/2020 | 11 | -112 | -99 | -92 | N/A |
| 12/31/2019 | 11 | -98 | -91 | -83 | N/A |
| 9/30/2019 | 10 | -86 | -75 | -69 | N/A |
| 6/30/2019 | 8 | -76 | -58 | -52 | N/A |
| 3/31/2019 | 6 | -72 | -47 | -44 | N/A |
| 12/31/2018 | 5 | -67 | -41 | -39 | N/A |
| 9/30/2018 | 4 | -63 | -40 | -38 | N/A |
| 6/30/2018 | 4 | -57 | N/A | -45 | N/A |
| 3/31/2018 | 4 | -47 | N/A | -42 | N/A |
| 12/31/2017 | 4 | -43 | N/A | -37 | N/A |
| 9/30/2017 | 4 | -38 | N/A | -34 | N/A |
| 6/30/2017 | 4 | -36 | N/A | -31 | N/A |
| 3/31/2017 | 4 | -35 | N/A | -30 | N/A |
| 12/31/2016 | 4 | -33 | N/A | -30 | N/A |
| 9/30/2016 | 4 | -33 | N/A | -29 | N/A |
| 6/30/2016 | 4 | -31 | N/A | -29 | N/A |
| 3/31/2016 | 4 | -30 | N/A | -19 | N/A |
| 12/31/2015 | 2 | -30 | N/A | -18 | N/A |
| 9/30/2015 | 1 | -29 | N/A | -18 | N/A |
| 6/30/2015 | 0 | -28 | N/A | -16 | N/A |
| 3/31/2015 | N/A | -27 | N/A | -24 | N/A |
| 12/31/2014 | N/A | -26 | N/A | -22 | N/A |
| 9/30/2014 | N/A | -25 | N/A | -21 | N/A |
| 6/30/2014 | 0 | -25 | N/A | -19 | N/A |
| 3/31/2014 | 0 | -24 | N/A | -17 | N/A |
| 12/31/2013 | 1 | -21 | N/A | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FATE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FATE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FATE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FATE's revenue (8.6% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: FATE's revenue (8.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FATE is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:48 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fate Therapeutics, Inc. is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Peter Lawson | Barclays |
| Etzer Darout | BMO Capital Markets Equity Research |